RetiSpec is an artificial intelligence (AI) medical imaging company developing tools for the early detection of disease biomarkers in the eye.
Our goal is to enable widespread early detection of Alzheimer’s disease with accessible and scalable screening.
In a quick eye exam, RetiSpec opens a window of opportunity for timely and specific therapeutic interventions, so the progression of the disease may be slowed or even prevented.
By harnessing hyperspectral imagery and AI, RetiSpec's patented technology allows for the rapid, simple, non-invasive, and cost-effective identification of Alzheimer's biomarkers.
RetiSpec is using computer vision and AI to detect unique signatures of Alzheimer’s biomarkers in a manner of seconds.
ELIAV SHAKED, M.SC
CEO & Co-founder
Eliav is a biomedical engineer with 7+ years experience managing R&D projects and having led several medical products from ideation to launch. He holds a B.Sc and M.Sc in Biomedical Engineering from Tel-Aviv University.
ROY KIRSHON, MBA
COO & Co-founder
Roy is a biomedical engineer, and an MBA. With 10 years of experience building new initiatives and working with ventures, Roy has lead new technologies and early stage startups to market.
CATHERINE BORNBAUM, PHD, MBA
Head of Clinical Operations & Partnerships
Catherine is a health scientist and MBA with 10+ years of experience leading large scale health research operations. In 2019, she was named one of the 100 Best & Brightest Executive MBAs globally by Poets & Quants.
ADAM GRIBBLE, PHD
ADAM GRIBBLE, PHD
Adam has 7 years of hands-on experience in both fundamental and applied optics research, including bio-imaging, spectral analysis, and development of optical instrumentation.
JARED WESTREICH, M.SC
Jared is an experienced data scientist with a background in medical biophysics and expertise in machine learning techniques.
ALON HAZAN, M.SC
Head of AI
Alon is an expert in artificial intelligence, deep learning and machine learning, and is a computer-vision researcher with over 10 years of industry experience, which includes designing two FDA approved AIs.
MAÏLIS BIETENHADER, PHD
Ocular Imaging Specialist
Mailis is an expert in ophthalmic imaging. After a PhD in Molecular Biology and a successful post-doctoral fellowship at the University of Toronto, she combines her background in research with 6 years of clinical experience.
In The News
Oct 05, 2020
RetiSpec Announces Partnership With Gentex To Commercialize Alzheimer's Disease Detection Technology
"The Gentex-RetiSpec partnership reinforces our commitment to bring to market RetiSpec's novel retinal imaging technology, a widely scalable and affordable way to accurately detect Alzheimer's Disease at both the symptomatic and pre-symptomatic stages," said Eliav Shaked, CEO of RetiSpec.
Oct 08, 2019
RetiSpec Receives Award from Alzheimer's Drug Discovery Foundation (ADDF)
Howard Fillit, M.D., Founding Executive Director and Chief Science Officer of ADDF, said, "We believe that RetiSpec's retinal scanner stands out and shows promise as a unique diagnostic tool among a range of technologies in development. The technology has the potential to facilitate early diagnosis, improve the lives of patients and their loved ones and save the healthcare system money and resources. The technology will also be useful in making clinical trials for Alzheimer's disease more efficient."
March 04, 2019
CABHI is working with RetiSpec to accelerate its technology in Ontario and Canada
The CABHI-funded RetiSpec trial will determine the safety and effectiveness of the technology through human clinical testing, and help spur commercialization of the technology in Ontario and Canada – to get it into the hands of those who need it most.
July 17, 2018
From the Lab to Life: A Retinal Scanner for Early Detection of Alzheimer’s Disease
Ontario Brain Institute backed RetiSpec to accelerate growth in Ontario, Canada. RetiSpec has developed software and “plug and play” hardware components that can be applied directly to existing retinal cameras readily found in optometrists’ offices.
Toronto, ON, Canada
© 2021 RetiSpec Inc. All rights reserved.
RetiSpec's technology is currently for research use only